Is CytoMed Therapeutics Ltd (GDTC) Stock a Good Investment?
Learn more about CytoMed Therapeutics Ltd's (GDTC) stock grades for Growth and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company’s lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Commentary & Analysis
Financial Summary
| Share Statistics | GDTC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $11.0 | $252.6 | 7% |
|
| Shares Out (Mil) | 9.1 | 52.3 | 20% |
|
| Institutional Ownership | 0.9% | 92.1% | 2% |
|
| Float (Mil) | 3.5 | 40.2 | 9% |
|
| Beta | -0.17 | 0.95 | 4% |
|
| Avg Daily Volume (000s) | 396 | 455 | 55% |
|
| Price Change (52-week) |
(52.1%) | 52.9% | 15% |
|
| Growth | GDTC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (15.6%) | (9.9%) | 24% |
|
| EPS (5yr) | (1.4%) | 16.0% | 29 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (34.8%) | (15.6%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | GDTC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $38 | 1% |
|
| Net Income (TTM) (Mil) | ($3) | ($43) | 35% |
|
| EPS (TTM) | ($0.266) | ($1.600) | 32% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($31) | 27% |
|
| Net Cash Flow (TTM) (Mil) | ($2) | $5 | 38% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 13% |
|
| Enterprise Value (Q1) (Mil) | $13 | $180 | 9% |
|
| Valuation | GDTC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.16 | 2.56 | 53% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | GDTC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 89.6% | 63.8% | 93% |
|
| Net Margin | (462.4%) | (67.3%) | 2% |
|
| ROA | (45.6%) | (49.8%) | 13% |
|
| ROE | (53.1%) | (55.5%) | 15% |
|
| Liabilities to Assets | 14.2% | 30.3% | 8% |
|
| F-Score | 2 | 3 | 7% |
|
CytoMed Therapeutics Limited did not pass any screens on 7/31/2026.
